Cencora (COR) to Release Quarterly Earnings on Wednesday

Cencora (NYSE:COR) is expected to be announcing its Q1 2026 results before the market opens on Wednesday, February 4th. Analysts expect Cencora to post earnings of $4.04 per share and revenue of $86.1184 billion for the quarter. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Interested persons may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:30 AM ET.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the business posted $3.34 EPS. The business’s revenue was up 5.9% compared to the same quarter last year. On average, analysts expect Cencora to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Cencora Stock Performance

COR stock opened at $356.15 on Wednesday. The firm has a market cap of $69.09 billion, a PE ratio of 44.80, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The stock has a 50-day moving average price of $348.17 and a 200-day moving average price of $323.06. Cencora has a 1-year low of $237.71 and a 1-year high of $377.54.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Insider Activity

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the sale, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 20,316 shares of company stock worth $7,151,265 over the last three months. 0.38% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Cencora

Several institutional investors have recently bought and sold shares of COR. Schonfeld Strategic Advisors LLC boosted its stake in Cencora by 85.5% in the third quarter. Schonfeld Strategic Advisors LLC now owns 1,293 shares of the company’s stock valued at $404,000 after acquiring an additional 596 shares during the last quarter. Eisler Capital Management Ltd. bought a new stake in shares of Cencora in the 3rd quarter worth approximately $299,000. State of Wyoming raised its holdings in shares of Cencora by 44.2% in the 2nd quarter. State of Wyoming now owns 1,070 shares of the company’s stock worth $321,000 after purchasing an additional 328 shares during the period. Evergreen Capital Management LLC grew its holdings in Cencora by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock valued at $370,000 after purchasing an additional 45 shares during the period. Finally, Modern Wealth Management LLC increased its position in Cencora by 7.6% in the second quarter. Modern Wealth Management LLC now owns 1,118 shares of the company’s stock worth $335,000 after buying an additional 79 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on COR shares. UBS Group raised their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Mizuho lifted their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Barclays began coverage on shares of Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. Finally, Wall Street Zen downgraded Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus price target of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.